Latest Headlines

  1. Lonza And Engitix Announce License Agreement To Advance Targeted ADC Development 7/21/2026

    Lonza, the world's leading contract development and manufacturing organization (CDMO), and Engitix, a global leader in ECM-based drug discovery and development, today announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs) and deliver life-changing therapies for patients with chronic diseases.

  2. Tract Bio Announces Presentations At Two AACR Conferences 7/21/2026

    Tract Bio ("Tract"), a biotechnology company discovering and developing novel therapies for cancer and inflammatory disease, today announced presentations at the American Association for Cancer Research Drug Discovery and Development (AACR D3) conference and the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers.

  3. Acrivon To Highlight The Power Of Its AP3 Platform For Streamlined, Pathway-Based Drug Discovery And Development With Oral And Poster Presentations At AACR D3 Conference 7/21/2026

    Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company will deliver an oral presentation and present a poster at the upcoming American Association for Cancer Research Drug Discovery and Development, or AACR D3, Conference, taking place July 21–24, 2026 in Boston.

  4. Phanes Therapeutics Announces Expansion Of Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Spevatamig In Combination With KEYTRUDA® (Pembrolizumab) And Chemotherapy For Treatment Of Biliary Tract Cancer 7/21/2026

    Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, has expanded their clinical trial collaboration with Merck (known as MSD outside of the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy in 1L BTC.

  5. TriLink BioTechnologies Further Strengthens Global IP Position With Newly Issued Patent In China For CleanCap Capping Technology 7/20/2026

    TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL 2025 1 1246578.X, covering methods of synthesizing RNA molecules.

  6. Biohaven To Present New Clinical Data At ESMO Congress On BHV-1530, A Novel FGFR3-Directed ADC With A Proprietary Topoisomerase I (TopoIx) Payload 7/20/2026

    Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, to be held October 23-27 in Madrid, Spain.

  7. Consano Bio Receives FDA Investigational New Drug Clearance To Expand The C-1101 Chronic Sciatica Clinical Development Program Into The United States 7/20/2026

    Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for C-1101, its lead investigational therapy for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica.

  8. Illumina Expands Billion Cell Atlas Program With New AI Drug Developers 7/16/2026

    Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio.

  9. Crown Bioscience Joins C-Path's NAMs Developer Coalition To Advance Human-Relevant Models In Drug Development 7/16/2026

    Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined Critical Path Institute's (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a collaborative initiative dedicated to advancing the validation, qualification and regulatory adoption of innovative human-relevant research methods.

  10. Novartis Fabhalta® (iptacopan) Receives FDA Traditional Approval As First And Only Complement Inhibitor To Significantly Slow Kidney Function Decline In Primary IgAN 7/16/2026

    Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta® (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression1.